-
A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
NCT06405087 ·
Phase: Phase 3 ·
Ages: 2 Years to 17 Years ·
Sex: All (male and female)
· California: Loma Linda, Orange, Palo Alto
-
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
NCT04844606 ·
Phase: Phase 3 ·
Ages: 2 Years to 19 Years ·
Sex: All (male and female)
· California: San Francisco
-
A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease
NCT07483073 ·
Phase: Phase 2 ·
Ages: 18 Years to 80 Years ·
Sex: All (male and female)
· California: Los Angeles, Oxnard
-
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
NCT06226883 ·
Phase: Phase 2 ·
Ages: 18 Years to 85 Years ·
Sex: All (male and female)
· California: Lancaster, San Diego
-
A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
NCT07499232 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· California: Anaheim, Lancaster, Los Alamitos, Los Angeles
-
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
NCT05923073 ·
Phase: Phase 3 ·
Ages: 2 Years to 17 Years ·
Sex: All (male and female)
· California: Los Angeles
-
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
NCT07196722 ·
Phase: Phase 2, Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· California: Anaheim, Canoga Park, Coronado, Lancaster
-
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
NCT07577843 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· California: Anaheim, Chula Vista, Los Alamitos, San Diego
-
A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease
NCT07483099 ·
Phase: Phase 2 ·
Ages: 18 Years to 80 Years ·
Sex: All (male and female)
· California: Los Angeles, Oxnard
-
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
NCT05509777 ·
Phase: Phase 3 ·
Ages: 2 Years to 17 Years ·
Sex: All (male and female)
· California: Los Angeles
-
A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
NCT06045754 ·
Phase: Phase 4 ·
Ages: 18 Years to 70 Years ·
Sex: All (male and female)
· California: La Jolla, Los Angeles, Newport Beach
-
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
NCT06227910 ·
Phase: Phase 3 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· California: La Jolla, Los Angeles
-
A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
NCT06581328 ·
Phase: Phase 4 ·
Ages: 18 Years to 80 Years ·
Sex: All (male and female)
· California: Escondido, Murrieta, Newport Beach, Orange
-
A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
NCT05442567 ·
Phase: Phase 3 ·
Ages: 2 Years and older ·
Sex: All (male and female)
· California: Los Angeles, San Diego, San Francisco
-
A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)
NCT04779320 ·
Phase: Phase 3 ·
Ages: 2 Years to 17 Years ·
Sex: All (male and female)
· California: Los Angeles, San Diego, San Francisco
-
A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
NCT06100289 ·
Phase: Phase 3 ·
Ages: 2 Years to 17 Years ·
Sex: All (male and female)
· California: Loma Linda, Orange, Palo Alto
-
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
NCT06233461 ·
Phase: Phase 2 ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female)
· California: Murrieta, Orange
-
A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
NCT05995353 ·
Phase: Phase 3 ·
Ages: 2 Years to 17 Years ·
Sex: All (male and female)
· California: Oakland
-
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
NCT06819891 ·
Phase: Phase 3 ·
Ages: 16 Years to 80 Years ·
Sex: All (male and female)
· California: Lancaster, Newport Beach, Pomona, Redwood City
-
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
NCT06819878 ·
Phase: Phase 3 ·
Ages: 16 Years to 80 Years ·
Sex: All (male and female)
· California: Garden Grove, Inglewood, La Jolla, Lancaster
-
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
NCT06430801 ·
Phase: Phase 3 ·
Ages: 16 Years to 80 Years ·
Sex: All (male and female)
· California: Anaheim, Coronado, Lancaster, Los Angeles
-
A Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's Disease
NCT06958536 ·
Phase: Phase 2 ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female)
· California: Escondido, Lancaster
-
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
NCT07184931 ·
Phase: Phase 3 ·
Ages: 16 Years to 80 Years ·
Sex: All (male and female)
· California: Canoga Park, Coronado, Folsom, Los Angeles
-
Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease
NCT05781152 ·
Phase: Phase 4 ·
Ages: 6 Years to 17 Years ·
Sex: All (male and female)
· California: Los Angeles, San Diego, San Francisco
-
Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
NCT06332534 ·
Phase: Phase 3 ·
Ages: 2 Years to 17 Years ·
Sex: All (male and female)
· California: Oakland, Palo Alto
-
Effect of Statins on Crohn's Disease
NCT06538649 ·
Phase: Early Phase 1 ·
Ages: 18 Years to 80 Years ·
Sex: All (male and female)
· California: Stanford
-
Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
NCT06456593 ·
Phase: Phase 2 ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female)
· California: Irvine, Murrieta
-
Impact of Prebiotics in Ulcerative Colitis
NCT06495658 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years to 85 Years ·
Sex: All (male and female)
· California: Los Angeles
-
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
NCT06937099 ·
Phase: Phase 3 ·
Ages: 18 Years to 70 Years ·
Sex: All (male and female)
· California: Anaheim, Beverly Hills, Los Alamitos, Northridge
-
Mirikizumab in the Treatment of Chronic Inflammatory Conditions of the Pouch
NCT06864403 ·
Phase: Phase 4 ·
Ages: 18 Years to 80 Years ·
Sex: All (male and female)
· California: Los Angeles
-
Moving Beyond Inflammation as a Therapeutic Target for Crohn's Disease
NCT06976853 ·
Phase: Phase 2 ·
Ages: 18 Years to 80 Years ·
Sex: All (male and female)
· California: Beverly Hills
-
Precise Infliximab Exposure and Pharmacodynamic Control
NCT05660746 ·
Phase: Phase 2, Phase 3 ·
Ages: 6 Years to 22 Years ·
Sex: All (male and female)
· California: Los Angeles, Palo Alto, San Diego
-
Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project
NCT02103361 ·
Phase: Not specified ·
Ages: No age limits stated ·
Sex: Female
· California: La Jolla
-
Stem Cell Transplantation in Crohn's Disease
NCT04224558 ·
Phase: Phase 1, Phase 2 ·
Ages: 13 Years to 28 Years ·
Sex: All (male and female)
· California: Los Angeles
-
Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
NCT07697456 ·
Phase: Phase 2 ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female)
· California: Anaheim, Lancaster, Los Alamitos, Rialto
-
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
NCT06548542 ·
Phase: Phase 2 ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female)
· California: Coronado, La Jolla, Sacramento, San Diego
-
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
NCT03816345 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· California: Palo Alto, Sacramento
-
Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission
NCT05230173 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· California: Irvine, La Jolla, Los Angeles, Palo Alto
-
Treatment of Moderate to Severe Refractory Crohn's Disease
NCT06721962 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· California: Sacramento, San Francisco
-
Urine Metabolites in the Diagnosis of Disease
NCT06710067 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· California: Encinitas, Santa Monica, Walnut Creek
-
VECTORS - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease
NCT06257706 ·
Phase: Phase 4 ·
Ages: 18 Years to 80 Years ·
Sex: All (male and female)
· California: Los Angeles